Metsera, Inc. (NASDAQ:MTSR – Free Report) – Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Metsera in a note issued to investors on Tuesday, February 25th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will earn ($3.38) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock.
A number of other research analysts have also recently issued reports on the company. Evercore ISI began coverage on Metsera in a research note on Tuesday. They set an “outperform” rating for the company. Bank of America started coverage on Metsera in a report on Tuesday. They set a “buy” rating and a $38.00 price target for the company. Finally, Guggenheim assumed coverage on shares of Metsera in a research report on Tuesday. They set a “buy” rating and a $56.00 price objective on the stock.
Metsera Price Performance
Shares of MTSR opened at $27.21 on Thursday. Metsera has a 52 week low of $25.06 and a 52 week high of $32.81.
Metsera Company Profile
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Further Reading
- Five stocks we like better than Metsera
- Airline Stocks – Top Airline Stocks to Buy Now
- These Consumer Staples Shine Amid Market Turmoil
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Regeneron: Is It the Perfect Biotech Stock for Value and Growth?
- 3 Monster Growth Stocks to Buy Now
- Axon: Long-Term Outlook Is Strong Despite Federal Budget Worries
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
